LGD1069
Term · Oncology and biomedicine · MLC-T-ONC-004816
A drug used to treat skin problems caused by cutaneous T-cell lymphoma that did not get better after other treatment. It is also being studied in the treatment of other types of cancer. LGD1069 binds to and activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. It is a type of retinoid. Also called bexarotene and Targretin.
| Identifier | MLC-T-ONC-004816 |
|---|---|
| Field | Oncology and biomedicine |
| Expansions | bexarotene; Targretin |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-004816",
"term": "LGD1069",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat skin problems caused by cutaneous T-cell lymphoma that did not get better after other treatment. It is also being studied in the treatment of other types of cancer. LGD1069 binds to and activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. It is a type of retinoid. Also called bexarotene and Targretin.",
"expansions": [
"bexarotene",
"Targretin"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/lgd1069/"
}
Record 10,074 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.